Table V.
Univariate and multivariate analysis using Cox's proportional hazard regression model for overall survival.
| Univariate analysis | Multivariate analysis | |||
|---|---|---|---|---|
| Clinicopathological parameters | HR (95% CI) | P-value | HR (95% CI) | P-value |
| Age (<60 vs. ≥60 years) | 1.422 (0.843-2.397) | 0.187 | ||
| Sex (male vs. female) | 1.332 (0.816-2.175) | 1.332 | ||
| Diabetes mellitus (yes vs. no) | 0.945 (0.504-1.771) | 0.860 | ||
| Tumor location (right vs. left) | 0.853 (0.512-1.421) | 0.540 | ||
| Vascular invasion (yes vs. no) | 2.467 (1.416-4.299) | 0.001 | 2.029 (1.156-3.562) | 0.014 |
| Lymphatic invasion (yes vs. no) | 2.976 (1.822-4.862) | <0.001 | 0.849 (0.476-1.515) | 0.580 |
| Perineural invasion (yes vs. no) | 2.869 (1.754-4.692) | <0.001 | 1.496 (0.863-2.594) | 0.151 |
| AJCC stage (I, II vs. III, IV) | 7.681 (4.097-14.401) | <0.001 | 7.211 (3.811-13.641) | <0.001 |
| TET2 (high vs. low) | 0.369 (0.182-0.748) | 0.006 | 0.369 (0.182-0.748) | 0.006 |
| AMPK (high vs. low) | 1.761 (1.061-2.921) | 0.028 | 1.288 (0.763-2.176) | 0.344 |
| AMPK high/TET2 low vs. AMPK low/TET2 high | 5.449 (2.043-14.533) | 0.001 | 3.304 (1.232-8.861) | 0.018 |
HR, hazard ratio; AMPK, AMP-activated protein kinase; TET2, ten eleven translocation 2; AJCC, American Joint Committee on Cancer.